FDA clears AstraZeneca's SGLT2-metformin combo Xigduo XR
This article was originally published in Scrip
Executive Summary
The FDA on 30 October gave its blessing to AstraZeneca to market its once-daily dapagliflozin and metformin combination pill Xigeuo XR as a treatment for adults with type 2 diabetes.